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We present a mathematical model that lends support to the hypothesis that estrogen levels mediate the complex relationship
between body mass index (BMI), menopausal status, estrogen-only hormone replacement therapy (HRT), and breast cancer risk.
The model predicts a decrease in the relative risk of breast cancer of 3% per unit increase in BMI (kg/m2)f o rp r e m e n o p a u s a l
women and an increase in the relative risk of 4% per unit increase in BMI for postmenopausal women who are not HRT users.
Whencomparingpostmenopausalwomenwhouseestrogen-onlyHRTtopostmenopausalwomenwhodonotuseHRT,themodel
predicts an increased risk of breast cancer associated with use of estrogen that diminishes with increasing BMI, with a relative risk
of 1.6 for women with BMI of 18, 1.2 for women with BMI of 25, and 1.0 for women with BMI ≥ 30. Model predictions agree with
data from ﬁve major epidemiological studies.
1.Introduction
The relationship between body mass index (BMI),
menopausal status, and breast cancer risk is complex.
In premenopausal women, higher BMI is associated with
a decreased risk of breast cancer, while in postmenopausal
women who do not use hormone replacement therapy
(HRT) higher BMI is associated with an increased risk of
breast cancer [1]. Use of HRT adds further complexity.
Postmenopausal women who use HRT have an increased
risk of breast cancer compared to postmenopausal women
who do not use HRT [2, 3]. The increased risk of breast
cancer associated with HRT use is attenuated in women
with high BMI [3]. Furthermore, the increased risk of breast
cancer associated with high BMI is not seen in women who
use HRT [4].
Estrogen pathways provide a biological explanation for
the relationship between BMI and breast cancer. For post-
menopausal women, estrogen levels increase with increasing
BMI, presumably because conversion of androgens to estro-
gen in adipose tissue is a primary source of estrogen [1, 5].
Estrogens have been shown to increase cell proliferation
in normal and malignant breast tissue [2]. Therefore, it
is regarded as biologically plausible that high levels of
circulating estrogens increase risk of breast cancer, and this
association has been observed in prospective studies [6, 7].
Since estrogen levels increase with BMI and breast cancer
risk increases with estrogen level, higher estrogen levels have
been hypothesized to be the mechanism behind the increase
in breast cancer risk for postmenopausal women with high
BMI [4, 8, 9]. The absence of an association between BMI
and breast cancer risk in postmenopausal women who take
HRT may be because elevated levels of circulating estrogens
due to HRT use dwarf the elevated levels due to high BMI.
Similarly, the attenuation of the increased risk of breast
cancer associated with HRT use in women with high BMI
m a yb eb e c a u s ew o m e nw i t hh i g hB M Ia l r e a d yh a v ee l e v a t e d
levels of circulating estrogens [4, 8].
Estrogen pathways also are hypothesized to explain
the relationship between BMI and breast cancer risk in
premenopausal women [4, 10]. Studies of estrogen in
premenopausal women are complicated by the fact that2 Computational and Mathematical Methods in Medicine
estrogen levels vary greatly during the menstrual cycle.
However, an association between high BMI and low estrogen
concentration is apparent when concentration is measured
duringthefollicularphaseofthemenstrualcycle[10].Lower
levels of estrogen during the follicular phase correspond to a
lower risk of breast cancer [11].
This qualitative explanation for the relationship between
BMI, menopausal status, and breast cancer risk based on
estrogen levels has been discussed in detail elsewhere [4,
8, 9, 12]. Other mechanisms, including insulin, insulin-
like growth factors, leptin, and adiponectin, have also been
proposed in the etiology of observed risk patterns [12, 13].
Among estrogens, free estradiol (estradiol not bound by
albumin or sex hormone binding globulin) is the most
biologically active form and has been associated with the
greatest increase in breast cancer risk in premenopausal and
postmenopausal women [6, 11].
In this study, we use a mathematical model to evaluate
the hypothesis that free estradiol levels drive the association
between BMI, menopausal status, estrogen-only hormone
replacement therapy, and breast cancer risk. We focus our
attention on estrogen-only HRT, also referred to as estrogen
replacement therapy (ERT), rather than combined estro-
gen/progestin hormone replacement therapy. Combined
hormone replacement therapy is associated with a greater
increase in risk of breast cancer than ERT [14], suggesting
the possibility of additional mechanisms at work. We assume
the existence of a saturation level for postmenopausal
women, above which additional amounts of free estradiol
do not incur additional risk. We compare the predictions
of the model to patterns of breast cancer risk observed in
epidemiological studies and randomized controlled trials.
2.MaterialsandMethods
We performed a search of MEDLINE using the MeSH
search terms: body mass index, estradiol, breast neoplasm,
risk factors, premenopause, postmenopause, menopause,
and hormone replacement therapy. We selected articles that
reported quantitative relationships between BMI, HRT, and
blood serum concentrations of free estradiol or between
blood serum concentrations of free estradiol and breast
cancer risk. We excluded articles that summarized data using
fewer than three strata for BMI, articles on premenopausal
women that did not report data on follicular phase estradiol
levels, and articles on postmenopausal women based on
fewer than 100 observations. We derived model inputs
from published meta-analyses where available; in particular,
reanalyses from the Endogenous Hormones and Breast
Cancer Collaborative Group were the primary source for
model inputs for postmenopausal women.
2.1. BMI and Postmenopausal Breast Cancer. We derived an
exponential relationship between BMI and free estradiol
concentration (E2F) from summary data from the reanalysis
of eight prospective studies reported in Table 2 of Key et al.
[9].ThisreanalysisexcludedwomenwhoweretakingHRTat
the time of blood collection. We estimated the median BMI
for each reported BMI category from the BMI distribution
for postmenopausal women in the National Health and
Nutrition Examination Surveys (NHANES) [15]. We ﬁt a
least-squares line to data points representing median BMIs
and mean log free estradiol concentrations (mol/L) for each
BMI category, yielding the following equation:
E2F = exp(0.068847 ·BMI −29.984). (1)
According to a reanalysis of nine prospective studies [6], the
relative risk of breast cancer per doubling of free estradiol
concentration among postmenopausal women who never
used HRT was 1.50 (95% CI 1.22–1.85), giving the equation
RR =

E1
2F
E2
2F
log21.5
, (2)
where RR is relative risk and E1
2F and E2
2F are two diﬀerent
concentrations of free estradiol.
Combining (1)a n d( 2) resulted in the following model
for relative risk of breast cancer in postmenopausal women
w h oa r en o tH R Tu s e r sa saf u n c t i o no fB M I( r e l a t i v et oa
reference BMI of 23):
RR =
exp(0.068847 ·BMI −29.984)
4.6325 ×10−13
log21.5
, (3)
which simpliﬁes to
RR = exp(0.040273 · BMI −0.92628). (4)
This represents an increase in relative risk by a factor of 1.04
for each unit increase in BMI (1kg/m2).
Several studies have observed a plateau in breast cancer
risk as a function of BMI for postmenopausal women with
BMI ≥ 30 [9, 16, 17]. In order to capture this eﬀect,
we hypothesized the existence of a saturation level for
postmenopausal women, above which additional amounts
of free estradiol do not incur additional risk. A proposed
saturation level of 7.50 × 10
−13 mol/L of free estradiol
corresponds to the concentration of free estradiol predicted
for a woman of BMI = 30 according to (1). This assumption
changed (2) for the relative risk of breast cancer associated
with free estradiol to
RR =

min(7.50 ×10−13,E1
2F)
min(7.50 ×10−13,E2
2F)
log21.5
,( 5 )
and (3) for the relative risk associated with BMI in post-
menopausal women who are not HRT users to
RR
=

min(7.50×10−13,exp(0.068847·BMI−29.984))
4.6325×10−13
log21.5
.
(6)
2.2. ERT and Postmenopausal Breast Cancer. We used the
same framework to develop a model for the eﬀect of
ERT on breast cancer risk, under the hypothesis that thisComputational and Mathematical Methods in Medicine 3
eﬀect is mediated primarily through free estradiol level.
The eﬀect of ERT on estradiol level was modeled using
summary data from the Nurses’ Health Study, in which
approximately 58% of women taking HRT used estrogen-
only preparations [8]. Current users of HRT had higher free
estradiol concentrations than nonusers. The ratio of free
estradiol in current users compared to nonusers decreased
with BMI and could be approximated by the equation
ratio = exp(−0.023098 · BMI+1.2617). (7)
We obtained an expression for the relative risk of breast
cancer as a function of BMI in ERT users, relative to a BMI
of 23, as follows. Let E1
2F and E2
2F represent the free estradiol
levels corresponding to an unspeciﬁed BMI and a BMI of 23,
respectively. From (1)a n d( 7),
E1
2F = exp(−0.023098 ·BMI+1.2617)
·exp(0.068847 · BMI −29.984)
= exp(0.045749 ·BMI −28.7223),
E2
2F = exp(−0.023098 ·23 + 1.2617)
·exp(0.068847 · 23 −29.984)
= 9.6155 × 10
−13.
(8)
Substituting into (5) and simplifying yields the following
equation:
RR
=

min

7.50×10−13,exp(0.045749·BMI−28.7223)

7.50×10−13
 log21.5
.
(9)
Similarly, the equation
RR
=

min[7.50×10−13,exp(0.045749·BMI−28.7223)]
min[7.50×10−13,exp(0.068847·BMI−29.984)]
 log21.5
(10)
models the relative risk of breast cancer associated with ERT
use for women of a ﬁxed BMI.
2.3. BMI and Premenopausal Breast Cancer. We constructed
a similar model to describe the inverse relationship between
BMI and breast cancer risk in premenopausal women.
We derived an exponential relationship between BMI and
follicular phase free estradiol concentration, using a least-
squares ﬁt to log-transformed data in Table 2 of Potischman
et al. [10]
E2F = exp(−0.039851 ·BMI −24.906), (11)
where E2F represents follicular free estradiol.
We estimated the relative risk of breast cancer associated
with a doubling of follicular free estradiol concentration as
1.7018 from Table 3 of Eliassen et al. [11], by ﬁtting a line
through the reference value to a log-log plot of relative risk
byfreefollicularestradiolconcentration.Theslopeoftheline
was 0.7671, so
0.7671 =
ln(RR1) −ln(RR2)
ln

E1
2F
	
−ln

E2
2F
	 , (12)
where E1
2F and E2
2F represent follicular free estradiol levels
andRR1 andRR2 representthecorrespondingrelativerisksof
breast cancer, relative to the ﬁxed reference value. Equation
(12) simpliﬁes to
RR =

E1
2F
E2
2F
log21.7018
, (13)
where RR = RR1/RR2 represents relative risk of breast cancer
for a follicular phase free estradiol concentration of E1
2F
relative to E2
2F.
Combining (11)a n d( 13) and simplifying leads to the
following model of premenopausal breast cancer relative risk
as a function of BMI, relative to a BMI of 23.
RR = exp(−0.030570 ·BMI+0.70307). (14)
This corresponds to a decrease in relative risk by a factor of
0.97 for each unit increase in BMI (1kg/m2).
3. Results
The model of BMI and breast cancer reported here supposes
that breast cancer risk associated with BMI is mediated
primarily by free estradiol, with no other important causes.
The model agrees with studies that measure relative risk
of breast cancer directly as a function of BMI, lending
support to this hypothesis. All of the data sources used
in the comparisons that follow were independent of those
used to build the model, with the exception of the Pooling
Project [16], which overlapped slightly with the reanalyses
[6, 9] used for model building; in addition, the hypothesized
saturation eﬀect was motivated in part by results from the
Pooling Project (see Table 1).
3.1. Model Predictions and Validation for Premenopausal
Women. Figure 1 compares the model’s predictions of rel-
ative risk of breast cancer associated with BMI in pre-
menopausal women with relative risks reported in analyses
from the Pooling Project [16], the European Prospective
Investigation into Cancer and Nutrition (EPIC) study [17],
and the Million Women Study [18]. In order to compare
thesestudies,whichuseddiﬀerentBMIcategories,weplotted
midpoints ofBMIcategories.Forthelowestandhighest BMI
category for each study, we estimated median BMIs from
NHANES data [15]. We rescaled relative risks to correspond
to a reference BMI of 23. This reference value was used
because it represents a typical and healthy BMI towards the
center of the BMI scale. Comparisons made with respect to a
BMIof23arelikelytoreﬂecttheoveralltrendofthedataand
are unlikely to be inﬂuenced by possible idiosyncratic eﬀects4 Computational and Mathematical Methods in Medicine
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Figure 1 :T h em o d e l ’ sp r e d i c t i o no ft h er e l a t i v er i s ko fb r e a s t
cancer associated with BMI in premenopausal women is compared
to the relative risks reported in three studies [16–18]. All relative
risks are rescaled to use a BMI of 23 as the reference value. Error
bars represent 95% conﬁdence intervals and are missing from data
points used as reference values in the original studies.
of extreme BMIs. We used a calibration plot to quantify
the agreement between model predictions and observed data
(see Figure 2). The model captures the trend of the data well
but predicts more extreme values of relative risk than the
observed values.
For premenopausal women, the model ﬁnds a reduction
in relative risk of 3% per unit increase in BMI (1kg/m2).
The Pooling Project reported an 11% reduction of relative
risk per 4kg/m2 increase in BMI, which is approximately a
3% reduction per unit increase in BMI [16]. An analysis of
EPIC data reported a nonsigniﬁcant 2% reduction of relative
risk per unit increase in BMI [17]. An analysis of the Million
Women Study found a decrease in relative risk by a factor
of 0.86 per 10kg/m2 increase in BMI, which is about a 1.5%
decrease per unit increase in BMI [18].
3.2. Model Predictions and Validation for Postmenopausal
Non-HRT Users. Figure 3 compares the model’s predictions
of relative risk of breast cancer associated with BMI in
postmenopausal women with relative risks reported in ﬁve
analyses, based on data from the Pooling Project [16],
the EPIC study [17], the Million Women Study [18], the
Cancer Prevention Study-II Nutrition Cohort [19], and the
Women’s Health Initiative [20]. As for the premenopausal
comparisons, relative risks for postmenopausal women were
rescaled to correspond to a reference BMI of 23. Model
predictions lie within the 95% conﬁdence intervals for
almost all of the studies and BMI categories. A calibration
plot shows excellent agreement between model predictions
a n do b s e r v e dd a t a( s e eFigure 4).
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Figure 2: Calibration plot for the premenopausal breast cancer
model, using observations from three studies [16–18]. The solid
line indicates perfect calibration; the dashed line is a regression line
(y = 0.8692 · x +0 .1028); the dotted line is a least-squares line,
weightedbythenumberofobservedbreastcancercasesrepresented
by each data point, an approximate measure of sample size (y =
0.5169 ·x +0.4623).
For postmenopausal women, the model ﬁnds a 4%
increase in relative risk per unit increase in BMI for non-
HRT users. An analysis of EPIC data reported a similar 3%
increaseinrelativeriskperunitincreaseinBMIfornon-HRT
users [17]. An analysis of the Million Women Study found
an increase in relative risk by a factor of 1.4 per 10kg/m2
i n c r e a s ei nB M If o rw o m e nw h oh a dn e v e ru s e dH R T ,w h i c h
is about a 3% increase per unit increase in BMI [18]. The
Pooling Project gave a smaller increase in relative risk of 7%
per 4kg/m2 increase in BMI, or slightly less than 2% per unit
increase in BMI [16]. The smaller eﬀect seen in the pooled
analysis may be because the investigators did not stratify by
HRT use.
3.3. Model Predictions and Validation for ERT. Although
the hypothesis of a saturation level is speculative, it helps
produce the correct interactions between BMI and HRT.
With the saturation assumption, the model predicts no
increase in relative risk of breast cancer associated with BMI
for postmenopausal women who are taking ERT, since ERT
use increases free estradiol levels beyond the hypothesized
saturation level regardless of BMI, for BMI ≥ 18. This model
prediction is consistent with observations from studies that
show no increase in relative risk of breast cancer associated
w i t hB M Ii nH R Tu s e r s[ 17, 19, 20].
When stratifying by BMI, the model predicts that the
relative risk of breast cancer associated with ERT use should
decrease from 1.6 in women with a BMI of 18 to 1.0 inComputational and Mathematical Methods in Medicine 5
Table 1: Studies used to validate the model.
Study Type of study Baseline cohort size Mean years of
followup Use for model validation
Pooling Project [16] Pooled reanalysis of 7
cohort studies Total∗ 337,819 3–8 Premenopausal and
postmenopausal models
EPIC [17] Prospective cohort
study
Premenopausal 73,542
4.7 Premenopausal and
postmenopausal models Postmenopausal
non-HRT users 79,030
Million Women Study
[14, 18]
Prospective cohort
study
Premenopausal 63,153
5.4
Premenopausal,
postmenopausal, and ERT
models
Postmenopausal
never users of HRT 392,757
current users of HRT 285,987
CPS-II [19]
Prospective cohort
study
Postmenopausal 8P o s t m e n o p a u s a l m o d e l
non-HRT users 41,159
WHI Observational
Study [20]
Prospective cohort
study
Postmenopausal 2.9 Postmenopausal model
never users of HRT 32,547
WHI Estrogen-Alone
Trial [21]
Randomized
controlled trial
Postmenopausal
7.1 ERT model non-HRT users 5,429
ERT users 5,310
∗Separate numbers of postmenopausal and premenopausal women included in the Pooling Project were unavailable.
women with a BMI of 30. This attenuation of the increased
risk of breast cancer for HRT use agrees with data reported
in Table 1 of Beral et al. [14], in which ERT users from
the Million Women Study are compared to never users of
HRT (see Figure 5) .H o w e v e r ,t h em o d e ld o e sn o ta g r e ew i t h
results from the Women’s Health Initiative, in which breast
cancer risk for ERT users was nonsigniﬁcantly decreased in
all BMI categories [21].
We used the model to predict an overall risk of breast
cancer associated with ERT by taking the average relative
risk over all values of BMI, weighted using the distribution
of BMI among postmenopausal women in NHANES. The
model predicts an overall relative risk of breast cancer
associated with ERT use of 1.15. Other estimates of the
relative risk of breast cancer associated with estrogen-only
HRTincludeanonsigniﬁcantdecreaseinrelativeriskof0.82,
(95% CI, 0.65–1.04) in the Women’s Health Initiative [21], a
relativeriskof1.3(95%CI,1.21–1.4)intheMillionWomen’s
Study [22], and a relative risk of 1.35 (95% CI, 1.21–1.49)
in the reanalysis by the Collaborative Group on Hormonal
Factors and Breast Cancer [3], in which 80% of HRT users
used primarily estrogen-only preparations. The relative risk
of 1.15 suggested by the model is plausible, given the range
of estimates in these studies.
4. Discussion
The ability of this mathematical model to capture complex
quantitative relationships suggests that estrogen levels are
indeed responsible for the relationship between BMI, ERT,
menopausal status, and breast cancer risk. Additional sup-
port for this hypothesis comes from an analysis of EPIC
data and a reanalysis by the Endogenous Hormones and
Breast Cancer Collaborative Group. Both analyses ﬁnd that
after adjusting for free estradiol concentration, the relative
risk of breast cancer associated with BMI in postmenopausal
women is not signiﬁcantly diﬀerent from 1.0 [9, 23].
The model proposes a threshold for free estradiol
concentration in postmenopausal women, beyond which
additional free estradiol does not incur additional risk of
breast cancer. This hypothesis is speculative yet compelling,
because it results in a model that neatly reproduces quanti-
tative observations with respect to three phenomena: (i) the
leveling oﬀ of breast cancer risk due to BMI for BMI > 30 in
postmenopausal women who do not use HRT, (ii) the lack of
eﬀectofBMIonbreastcancerriskforpost-menopausalHRT
users, and (iii) the attenuated eﬀect of HRT on breast cancer
risk for women with high BMI. Alternatively, it is possible
that additional free estradiol beyond a certain concentration
has a gradually decreasing eﬀect on breast cancer risk rather
than no eﬀect. Available data on free estradiol and breast
cancer risk could be used to test these hypotheses and to
determine where the proposed threshold might lie.
The model has a number of limitations. First, the model
wasbasedonsummarydatafromanumberofdiﬀerentstud-
ies, which necessitated certain approximations. For example,
summary data points, rather than individual level data,
were used to estimate the relative risk of breast cancer per
doubling of estradiol for premenopausal women. A second
limitation is the variability in estradiol concentrations based
on the assay used [6]. However, because the relative risk of
breast cancer was represented as a function of doubling of
free estradiol levels instead of absolute free estradiol levels,
this variability should have minimal eﬀect on the model’s
predictions of relative risk associated with BMI and ERT use.
A third limitation is that the data from the Nurses Health
Study used to model the eﬀect of ERT on free estradiol levels6 Computational and Mathematical Methods in Medicine
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combined diﬀerent doses and forms of HRT [8]. Therefore,
the model of the eﬀect of ERT on free estradiol levels reﬂects
average or typical use of HRT rather than any one particular
dose or form. Some inaccuracy may result from using data
that includes women taking combined HRT to represent the
eﬀect of estrogen-only HRT on estradiol levels.
Another limitation of the model for premenopausal
women is that the underlying equations are based on
limited data. Evidence from additional studies of hormone
levels in premenopausal women was not used to build
this model because the authors did not report follicular
phasefreeestradiolconcentrations[24–29].However,several
of these studies do show relationships between BMI and
total estradiol concentrations in premenopausal women that
are heterogeneous in nature. For example, Thomas et al.
and Randolf et al. found a smaller decrease in follicular
phase total estradiol concentration with increasing BMI than
was found by Potischman et al. and used in the model
[10, 24, 25]. Verkasalo et al. did not observe a trend of
decreasing total estradiol concentration as a function of
BMI, when using data from all phases of the menstrual
cycle and adjusting for day of the cycle [26]. Emaus et al.
found that multivariate adjusted total estradiol concentra-
tion in the saliva increased with BMI [27]. Because the
concentrationoffreeestradiolisprimarilydeterminedbythe
concentrations of total estradiol and sex hormone binding
globulin, variations in the relationship between BMI and
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Figure 4: Calibration plot for the postmenopausal breast cancer
model, using observations from ﬁve studies [16–20]. The solid line
indicates perfect calibration; the dashed line is a regression line
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weightedbythenumberofobservedbreastcancercasesrepresented
by each data point, an approximate measure of sample size (y =
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BMI > 30.
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total estradiol levels found by diﬀerent studies may indicate
a more subtle relationship between BMI and follicular free
estradiol level than is accounted for by the model. The
possibility remains that other factors, such as obesity-related
anovulation or alterations in hormones other than estrogen,
may be important components of the explanation of the
inverseassociationofBMIwithpremenopausalbreastcancer
risk.
Thecurrentmodelexplainsknownrelationshipsbetween
BMI, ERT, and breast cancer risk in a mathematical frame-
work that can be extended and reﬁned. The model could
potentially be used to estimate the eﬀect of weight loss
on breast cancer risk reduction, through estrogen pathway
changes. In addition, it may be possible to incorporate phys-
ical activity into this estrogen model, since there is evidence
that the protective eﬀect of physical activity on breast cancer
risk may be mediated through estrogen levels [30]. The
model can easily be expanded to include total estradiol and
sex hormone binding globulin, since concentrations of total
estradiol and sex hormone binding globulin determine the
concentration of free estradiol based on the law of mass
action [31]. The model could also be improved by including
combined HRT and the additional eﬀect of progestin on
breast cancer risk. Although combined HRT has a greater
eﬀectonbreastcancerriskthanestrogen-onlyHRT,thesame
patterns of interaction with BMI have been observed for
both types of HRT [32]. Finally, the model could be reﬁned
to reﬂect the greater eﬀect of estradiol on estrogen-receptor
positive than estrogen-receptor negative breast cancer [33].
5. Conclusion
The estrogen-based mathematical model presented here
predicts patterns in breast cancer risk that quantitatively
agree with observations from epidemiological studies and
randomized clinical trials, including the European Prospec-
tive Investigation into Cancer and Nutrition, the Million
Women Study, the Cancer Prevention Study II, and the
Women’s Health Initiative. The model thus gives mathe-
matical support to the hypothesis that estrogen levels are
largely responsible for complex relationships between BMI,
menopausal status, ERT use, and breast cancer risk.
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